TEL AVIV – Industrializing "luck" may open the door to a motherlode that the biopharmaceutical industry may be currently ignoring. One path to faster drug development, said Daphna Leifenfeld, is repurposing of existing drugs. This not only makes sense, but is something that the pharmaceutical industry should do more of, she said at the 17th Mixiii-Biomed Conference this week. The meeting in Israel is focused on trends shaping the future of health care systems and life sciences.

TEL AVIV, Israel – A presentation in early June to the American Society of Clinical Oncology (ASCO) will mark yet another small step in Israeli firm Compugen Ltd.'s ongoing effort to transform itself from a computational drug target discovery company into a preclinical or even clinical-stage drug company.

TEL AVIV, Israel – One of the most visible contingents of investors and industry people during the recent MIXiii Biomed conference came from China. Two large delegations brought in more than 170 participants, a Chinese researcher gave one of the keynotes on aging and for some delegates there was simultaneous translation in Mandarin.

TEL AVIV, Israel – Israel has plenty of innovators and researchers and is pumping out new innovative ideas and research at record speed, but a lack of infrastructure may be holding the industry back and preventing the emergence of companies of global stature.

TEL AVIV, Israel – One of the most visible contingents of investors and industry people during the recent MIXiii Biomed conference came from China. Two large delegations brought in more than 170 participants, a Chinese researcher gave one of the keynotes on aging, and for some delegates, there was simultaneous translation in Mandarin.

TEL AVIV, Israel – Israel has plenty of innovators and researchers and is pumping out new innovative ideas and research at record speed, but a lack of infrastructure may be holding the industry back and preventing the emergence of companies of global stature.

TEL AVIV, Israel – A presentation in early June to the American Society of Clinical Oncology (ASCO) will mark yet another small step in Israeli firm Compugen Ltd.'s ongoing effort to transform itself from a computational drug target discovery company into a preclinical or even clinical-stage drug company.